The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Expanding access to gene therapy for patients with sickle cell disease
Sunil Gupta, MD, FRCP, FRCPath, MBA, Lewisham and Greenwich NHS Trust, London, UK, discusses the current state of sickle cell disease (SCD) treatment in the UK, highlighting the need for increased accessibility to gene therapy, He emphasizes the importance of fast-tracking patients with SCD for gene therapy, considering their poor quality of life and potential for organ damage. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
